TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male Age 45 or older~* Histologically confirmed adenocarcinoma of the prostate~* Disease Staging III or IV~* Clinical indication for androgen suppression therapy~* Serum testosterone at least 150 ng/dL at screening~* WHO Performance Scale 0 to 3~* Life expectancy of at least one year~Key Exclusion Criteria:~* Bilateral orchiectomy~* Prior androgen-ablative therapy within past year~* Second malignancy with 5 years (except adequately treated non-melanomatous skin cancer or superficial bladder cancer)~* Spinal cord compression

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- one histrelin acetate 50 mg implant (Type: EXPERIMENTAL): The test product was a histrelin acetate 50 mg hydrogel implant surgically placed subdermally into the inner aspect of the upper arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects will be men and women of all races and ethnic backgrounds aged 45-65 years.~* Subjects will be prehypertensive/hypertensive defined as resting systolic blood pressure \>125 mmHg and \<160 mmHg and/or diastolic \>80 mmHg and \<100 mmHg.~* All of the women in the study will be postmenopausal and not receiving hormone replacement therapy (HRT) currently or in the preceding 3-year period.~* Candidates will be sedentary as determined from the Stanford Physical Activity Questionnaire (\<35 kcal/wk) and will not have engaged in any program of regular physical activity for at least 1 year prior to the study.~Exclusion Criteria:~* Candidates who smoke (currently or in the past 7 years), report more than low-risk alcohol consumption as defined as no more than 14 standard drinks/wk and no more than 4 standard drinks/day for men and 7 standard drinks/wk and 3 standard drinks/day for women (a standard drink is defined as 12 ounces of beer, 5 ounces of wine, 1½ ounces of 80-proof distilled spirits).~* Potential candidates who are taking cardiovascular-acting (i.e. statins, blood pressure medication and aspirin) medications will not be eligible.~* Fasting plasma glucose \>126 mg/dL.~* Potential candidates with a resting heart rate of \< 50 beats/minute will be excluded.~* Use of hormone replacement therapy.~* In hypertensive subjects, a seated systolic blood pressure \>160 mmHg or a seated diastolic blood pressure \>100 mmHg will be excluded.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Nebivolol (Type: ACTIVE_COMPARATOR): None
- Metoprolol (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- Bradykinin (Type: OTHER): None
- Saline (Type: OTHER): None
- Vitamin C (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Transcutaneous Electrical Acupoint Stimulation of P6 to Prevent Postoperation Nausea and Vomiting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists (ASA) physical status I or II~* aged between 18 to 60yr~* scheduled for elective gynecological laparoscopic surgery requiring general anesthesia~Exclusion Criteria:~* pregnancy or breastfeeding~* mental retardation~* psychiatric or neurological disease~* use of antiemetics, emetogenic drugs, opioids or glucocorticosteroids within 3 days prior to surgery~* known allergy to tropisetron or dexamethasone~* nausea and/or vomiting within 24 hr prior to surgery~* implantation of a cardiac pacemaker, cardioverter, or defibrillator~* any skin problem at the acupoint stimulation area

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Acustimulation (Type: EXPERIMENTAL): Transcutaneous electrical acupoint stimulation (TEAS) starts 30 min before surgery and lasts until patient leaves the postanesthetic care unit.Dexamethasone 10mg i.v. after induction.
- Tropisetron (Type: ACTIVE_COMPARATOR): Tropisetron 5mg iv. at the start of skin closure.Sham transcutaneous electrical acupoint stimulation.Dexamethasone 10mg i.v.after induction.
- Control (Type: SHAM_COMPARATOR): Sham transcutaneous electrical acupoint stimulation. Dexamethasone 10mg i.v.after induction.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with hidradenitis suppurativa Hurley stage I or II~Exclusion Criteria:~* Current systemic immunosuppression, current use of biologic medication or use of these medications in the prior 3 months, patients with known retinal disease, hepatic disease (HCV, cirrhosis, aspartate aminotransferase or alanine aminotransferase \> 2 times the upper limit of normal), psoriasis, porphyria cutanea tarda, platelets \< 50,000/ul, leukocytes \<4000/ul, or Hb\<8g/dl), pregnant patients or women trying to conceive

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hydroxychloroquine treatment (Type: EXPERIMENTAL): Hydroxychloroquine 200mg BID for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Geodon for the Treatment of Refractory Social Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* adults 18-65 years of age~* primary diagnosis of SAD, using Diagnostic Standard Manual(DSM-IV) criteria~* minimum Clinical Global Impression of Severity (CGI-S) score of 4 at baseline~* minimum Brief Social Phobia Scale(BSPS) score of 20 at baseline~* written informed consent~* negative serum pregnancy test for women of childbearing potential~* normal EKG~Exclusion Criteria:~* current DSM-IV diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, mental retardation or other pervasive developmental disorder, or cognitive disorder due to a general medical condition~* any current primary anxiety disorder other than SAD~* current primary depression~* history of substance abuse or dependence within the last 3 months~* suicide risk or serious suicide attempt within the last year~* clinically significant medical condition or laboratory or EKG abnormality~* women of childbearing potential who are unwilling to practice an acceptable method of contraception~* patients needing concurrent use of psychotropic medications~* history of hypersensitivity to sertraline or ziprasidone~* recent (less than 2 months) initiation of psychotherapy for SAD~* history of failure to respond to augmentation with an adequate trial of an atypical antipsychotic~* patients who are currently taking any of the following medications: Erythromycin, Biaxin, Avelox, Zithromax, Amantadine, Levaquin, Tamoxifen, Tegretol, Nizoral, and Levitra

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Open Label Treatment (Type: OTHER): 8 weeks of open label treatment with sertraline
- Randomization Ziprasidone (Type: OTHER): 8 weeks of treatment with sertraline augmented with ziprasidone
- Randomization Placebo (Type: OTHER): 8 weeks of treatment with sertraline augmented by placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-65 years old~* Creatinine clearance (Ccr) \< 15 ml/min/1.73 m2~* Anti-HCV (Abbott HCV EIA 3.0, Abbott Diagnostic, Chicago, IL) positive \> 6 months~* Detectable serum quantitative HCV-RNA (Cobas Taqman HCV test, version 2, Roche Diagnostics) with a dynamic range of 25-391000000 IU/ml~Exclusion Criteria:~* Receiving interferon-based therapy for chronic hepatitis C~* Severe anemia (hemoglobin \< 10 g/dL) or hemoglobinopathy~* Neutropenia (neutrophil count, \<1,500/mm3)~* Thrombocytopenia (platelet \<90,000/ mm3)~* Co-infection with HBV or HIV~* Chronic alcohol abuse (daily consumption \> 20 g/day)~* Autoimmune liver disease~* Decompensated liver disease (Child classification B or C)~* Neoplastic disease~* An organ transplant~* Immunosuppressive therapy~* Poorly controlled autoimmune diseases, pulmonary diseases, cardiac diseases, psychiatric diseases, neurological diseases, diabetes mellitus~* Evidence of drug abuse~* Unwilling to have contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Peginterferon alfa-2a and ribavirin (Type: EXPERIMENTAL): Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
- Peginterferon alfa-2a (Type: EXPERIMENTAL): Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Paravertebral Block for Inguinal Hernia Repair in Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients admitted to undergo elective unilateral inguinal hernia repair~* patients with ASA II, III or IV~Exclusion Criteria:~* bilateral inguinal hernia~* incarcerated hernia~* emergency cases~* known history of allergic reactions to local anesthesia~* bleeding disorders~* neurological disorders~* infection at site of injection

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Three PVB injections (Type: EXPERIMENTAL): Patients will receive three PVB injections from T12 to L2 and placebo at T11 and L3
- Five PVB injections (Type: EXPERIMENTAL): Patients will receive five PVB injections between T11 and L3.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Resin Infiltration to Arrest Early Tooth Decay

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DMFT ≥ 3 (DMFT = index of decayed-missing-filled permanent teeth)~* Having at least two early caries lesions in approximal posterior tooth surfaces~* Lesions visible on radiograph~Exclusion Criteria:~* Current participation in another clinical study~* Medically compromised subjects~* Hyposalivation~* Pregnancy~* Allergic to methylmethacrylates~* Allergic to latex~* Symptomatic teeth

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 24 Years
- Healthy Volunteers: f

Study Arms:
- Resin infiltration (Type: ACTIVE_COMPARATOR): Resin infiltration of early caries lesion in addition to preventative measures (oral hygiene, diet counseling, repeated fluoride varnish application)
- Control (Type: SHAM_COMPARATOR): Sham treatment of early caries lesion in addition to preventative measures (oral hygiene, diet counseling, repeated fluoride varnish application)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dietary Nitrate and Exercise to Augment Exercise Training Benefits in Subjects With DM+PAD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Peripheral Arterial Disease (ABI of less than 0.9)~* Diagnosed Type II Diabetes~* Intermittent Claudication for 3 or more months~Exclusion Criteria:~* Individuals with known alcohol or drug abuse problems~* Individuals who have suffered a heart attack or stroke, or have changes on a resting ECG, in the last 3 months~* Those classified as American Heart Association Class D~* Gangrene, impending limb loss or osteomyelitis~* Lower extremity vascular surgery, angioplasty or lumbar sympathectomy within 3 months of enrollment~* Severe peripheral neuropathy~* Any condition other than PAD that limits walking~* Chest pain during treadmill exercise which appears before the onset of claudication, or \>3mm ST depression during exercise~* Subjects taking nitrates or nitroglycerin products~* Must not be taking protein pump inhibitor medications

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BR Juice (Beet-It Stamina Shot) & Supervised Exercise Training (Type: EXPERIMENTAL): Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 \& 2) and at the end of the trial (between Visits 3 \& 4). It also allows for comparisons of the combination of beetroot juice and chronic training effects (between Visits 2 \& 3) to when the subject has not consumed the beverage (Visits 1 \& 4). All subjects will consume Beet-It Stamina Shot 3 hours prior to all beverage tolerance visits, Testing Visits 2 \& 3 and for all supervised exercise training visits during the 12 week intervention.
- BR Juice Placebo and Exercise Training (Type: PLACEBO_COMPARATOR): Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot; Placebo) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 \& 2) and at the end of the trial (between Visits 3 \& 4). It also allows for comparisons of the combination of placebo beverage and chronic training effects (between Visits 2 \& 3) to when the subject has not consumed the beverage (Visits 1 \& 4). All subjects will consume Beet-It Stamina Shot (Placebo) 3 hours prior to all beverage tolerance visits, Testing Visits 2 \& 3 and for all supervised exercise training visits during the 12 week intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female COPD subjects between the ages of 40 and 80 years~* Body mass index between 18 and 35~* Medically healthy (other than COPD)~* FEV1/FVC less than or equal to 0.70~* Current non-smoker or able to abstain from smoking for at least 8 hours postdose~* Within the previous 6 months, demonstrated improvement in FEV1 (greater than or equal to 10%) 1 hour following administration of ipratropium bromide inhalation (4 puffs)~* Females of childbearing potential must agree to use an acceptable method of contraception for the duration of the study~Exclusion Criteria:~* Asthma in the last 10 years~* Allergic rhinitis, atopy, cystic fibrosis, bronchiectasis, or tuberculosis~* Bladder neck obstruction, including urinary retention or known symptomatic prostatic hypertrophy not controlled with medication~* Narrow angle glaucoma~* Tachyarrhythmia~* Alcohol dependence or illicit drug abuse within the past year~* Using long-term oxygen therapy~* Female subjects who are pregnant or breastfeeding~* Participating in another clinical trial

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Represents Dose A in the Dosing Sequence assignments.
- TrIP-2D (100mcg) (Type: EXPERIMENTAL): Represents Dose B
- TrIP-2SS (100mcg) (Type: EXPERIMENTAL): Represents Dose C
- TrIP-2D (400mcg) (Type: EXPERIMENTAL): Represents Dose D
- TrIP-2SS (100mcg) + Foradil (12mcg) (Type: EXPERIMENTAL): Represents Dose E. All subjects received Dose E as their final (5th) dose, after completing their initial 4 single doses according to their sequence assignment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Research Study in Patients With Persistent Macular Edema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion: Persistent macular edema associated with diabetic retinopathy, uveitis, retinal vein occlusion, or Irvine-Gass syndrome, persisting at least 90 days after laser treatment or medical management by a physician.~Exclusion: Females who are pregnant or lactating, and females of childbearing potential not using adequate birth control for the duration of the study. Any intraocular procedures or laser treatment less than 90 days before enrollment.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Based on medical history, evidence of TG ≥ 500 mg/dL and ≤ 4000 mg/dL at Screening~* Fasting TG ≥ 500 mg/dL at Screening~* Willing to follow diet counseling per Investigator judgment based on local standard of care~* Women of childbearing potential must have a negative pregnancy test, cannot be breastfeeding, and must be willing to use contraception~* Willing to provide written informed consent and to comply with study requirements~Exclusion Criteria:~* Active pancreatitis within 12 weeks prior to first dose~* Any planned bariatric surgery or similar procedures to induce weight loss from consent to end of study~* Acute coronary syndrome event within 24 weeks of first dose~* Major surgery within 12 weeks of first dose~* Planned coronary intervention (e.g., stent placement or heart bypass) or any non-cardiac major surgical procedure throughout the study~* Uncontrolled hypertension~* Human immunodeficiency virus (HIV) infection, seropositive for Hepatitis B (HBV), seropositive for Hepatitis C (HCV)~* Uncontrolled hypothyroidism or hyperthyroidism~* Hemorrhagic stroke within 24 weeks of first dose~* Malignancy within the last 2 years prior to date of consent requiring systemic treatment (some exceptions apply)~Note: additional inclusion/exclusion criteria may apply per protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ARO-APOC3 10 mg, Day 1 and Week 12 (Type: EXPERIMENTAL): 2 doses of ARO-APOC3 by subcutaneous (sc) injection
- ARO-APOC3 25 mg, Day 1 and Week 12 (Type: EXPERIMENTAL): 2 doses of ARO-APOC3 by sc injection
- ARO-APOC3 50 mg, Day 1 and Week 12 (Type: EXPERIMENTAL): 2 doses of ARO-APOC3 by sc injection
- Placebo, Day 1 and Week 12 (Type: PLACEBO_COMPARATOR): calculated volume to match active treatment by sc injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Propranolol in Newborns With Retinopathy of Prematurity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Infants who have been screened for ROP (≤ 32 weeks gestation) who develop Stage 2 ROP in zone II without plus.~2. Informed Consent from a parent~Exclusion Criteria:~1. Newborns with one or more of the following conditions at the enrollment in the study:~   * Heart failure.~  * Recurrent episodes of bradycardia (Heart rate less than 90 bpm).~  * Atrio-ventricular block (second or third degree).~  * Significant congenital heart anomaly, not including patent ductus arteriosus, patent foramen ovale or small ventricular septal defect.~  * Hypotension.~  * Renal failure.~  * Cerebral hemorrhage.~  * Other diseases which contraindicate the use of beta-blockers~2. Newborns with ROP stages more advances than Stage 2 in zone II without plus.~3. Informed Consent from a parent refused. This will mean that an infant automatically will receive standard laser therapy. No data will be used from an infant without Informed Consent.

- Gender: ALL
- Minimum Age: 22 Weeks
- Maximum Age: 32 Weeks
- Healthy Volunteers: f

Study Arms:
- Propranolol (Type: EXPERIMENTAL): Oral Propranolol administration is the experimental arm of this study
- Control (Type: NO_INTERVENTION): Control arm is treated following the standard treatment schedule of Early Treatment For Retinopathy Of Prematurity Cooperative Group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete